3SN-18023-40127
1 vaccination
1 coded response
3 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 100 / NY
- Registered
- 2022-02-26
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Hispanic or Latino
Timeline
-
2022-02-26
Registered in v-safe
-
2022-02-26
Dose 1 — Pfizer-BioNTech
- 2022-02-26
-
2022-02-27
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Swelling · Muscle or body aches, Fatigue or tiredness · Be unable to work or attend schoolAdult check-in
-
2022-02-28
Survey response — days 1–6 daily, dose 1MedDRA: Nasal congestion, Oropharyngeal pain — Feeling: Poor · Fatigue or tiredness · Be unable to work or attend schoolFree text: congested nose and sore throatMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-02-26 | Pfizer-BioNTech | No |
Free text
Release 11 — days 1–6 daily, dose 1
Systemic reaction (other): congested nose and sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Nasal congestion | · | · | ✓ |
| SRO | Oropharyngeal pain | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release